Loading...

Expanding Targeted Therapies And Biosimilars Will Shape Market Trends

Published
18 Jul 24
Updated
07 May 25
n/a
n/a
AnalystConsensusTarget's Fair Value
n/a
Loading
1Y
18.7%
7D
5.2%

Author's Valuation

US$311.888.0% overvalued intrinsic discount

AnalystConsensusTarget Fair Value

Shared on 07 May 25

Fair value Decreased 2.12%

Shared on 30 Apr 25

Fair value Decreased 1.13%

AnalystConsensusTarget made no meaningful changes to valuation assumptions.

Shared on 23 Apr 25

Fair value Decreased 0.28%

AnalystConsensusTarget made no meaningful changes to valuation assumptions.

Shared on 16 Apr 25

Fair value Decreased 0.14%

AnalystConsensusTarget made no meaningful changes to valuation assumptions.

Shared on 09 Apr 25

Fair value Increased 0.51%

AnalystConsensusTarget has increased revenue growth from 3.0% to 3.4%.

Shared on 02 Apr 25

Fair value Increased 2.01%

AnalystConsensusTarget made no meaningful changes to valuation assumptions.

Shared on 26 Mar 25

AnalystConsensusTarget made no meaningful changes to valuation assumptions.

Shared on 19 Mar 25

AnalystConsensusTarget made no meaningful changes to valuation assumptions.

Shared on 10 Mar 25

Fair value Increased 0.30%

AnalystConsensusTarget made no meaningful changes to valuation assumptions.